Patents Assigned to Cytokinetics
-
Patent number: 11964967Abstract: Provided are compounds of Formula (I): or a pharmaceutically acceptable salt thereof, wherein X, R1, R2, and R3 are as defined herein. Also provided is a pharmaceutically acceptable composition comprising a compound of Formula (I), or a pharmaceutically acceptable salt thereof. Also provided are methods of using a compound of Formula (I), or a pharmaceutically acceptable salt thereof.Type: GrantFiled: June 25, 2019Date of Patent: April 23, 2024Assignee: Cytokinetics, Inc.Inventors: Bradley P. Morgan, Chihyuan Chuang
-
Patent number: 11958809Abstract: Provided are omecamtiv mecarbil dihydrochloride salt forms, compositions and pharmaceutical formulations thereof, and methods for their preparation and use.Type: GrantFiled: September 24, 2021Date of Patent: April 16, 2024Assignee: CYTOKINETICS, INC.Inventors: Sheng Cui, Henry Morrison, Karthik Nagapudi, Shawn D. Walker, Charles Bernard, Karl Bennett Hansen, Neil Fred Langille, Alan Martin Allgeier, Steven M. Mennen, Jacqueline C. S. Woo, Bradley Paul Morgan, Alex Muci
-
Patent number: 11952381Abstract: Provided are compounds of Formula (I): or a pharmaceutically acceptable salt thereof, wherein R1, R2A, R2B, R3, R4, and R5 are as defined herein. Also provided is a pharmaceutically acceptable composition comprising a compound of Formula (I), or a pharmaceutically acceptable salt thereof. Also provided are methods of using a compound of Formula (I), or a pharmaceutically acceptable salt thereof.Type: GrantFiled: May 4, 2022Date of Patent: April 9, 2024Assignee: CYTOKINETICS, INC.Inventors: Chihyuan Chuang, Bradley P. Morgan, Mark Vanderwal, Luke W. Ashcraft, Kevin Lau
-
Patent number: 11931358Abstract: Provided herein are methods of treating a subject with heart failure, comprising administering to the subject an initial dose of a cardiac sarcomere activator (CSA) for an initial time period, and subsequently administering to the subject a dose of the CSA based on the subject's plasma concentration of the CSA at the end of the initial time period.Type: GrantFiled: May 5, 2023Date of Patent: March 19, 2024Assignees: AMGEN INC., CYTOKINETICS, INC.Inventors: Narimon Honarpour, Fady Malik
-
Patent number: 11932631Abstract: Provided herein is a process for the preparation of (R)—N-(5-(5-ethyl-1,2,4-oxadiazol-3-yl)-2,3-dihydro-1H-inden-1-yl)-1-methyl-1H-pyrazole-4-carboxamide, intermediates thereof, and salts of the foregoing.Type: GrantFiled: August 2, 2022Date of Patent: March 19, 2024Assignee: CYTOKINETICS, INC.Inventors: Denise Andersen, Matthew Pfeiffer, Norma Tom, Bradley P. Morgan
-
Patent number: 11919909Abstract: Provided are compounds of Formula (I): or stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein R1, R2, R3, and R4 are as defined herein. Also provided is a pharmaceutically acceptable composition comprising a compound of Formula (I), or stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing. Also provided are methods of using a compound of Formula (I), or stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing.Type: GrantFiled: March 3, 2022Date of Patent: March 5, 2024Assignee: CYTOKINETICS, INC.Inventors: Bradley P. Morgan, Chihyuan Chuang, Luke W. Ashcraft, Justin Ho, Alfredo Garcia
-
Patent number: 11884630Abstract: Provided are certain pharmaceutical formulations of omecamtiv mecarbil and methods for their preparation and use.Type: GrantFiled: June 8, 2022Date of Patent: January 30, 2024Assignee: CYTOKINETICS, INC.Inventors: Mingda Bi, Robert Kuehl
-
Patent number: 11780826Abstract: The present invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof, pharmaceutical compositions comprising a compound of the invention, a method for manufacturing compounds of the invention and therapeutic uses thereof.Type: GrantFiled: February 15, 2022Date of Patent: October 10, 2023Assignees: AMGEN INC., CYTOKINETICS, INC.Inventors: Luke Ashcraft, Alessandro Boezio, John Butler, Aroop Chandra, Chihyuan Chuang, Scott E. Collibee, Mikkel Debenedetto, Vincent Dimassa, Russell Graceffa, Justin Malinowski, David Moebius, Bradley P. Morgan, Joshua Payette, Antonio Romero, David St. Jean, Jr., Richard Vargas, John Yeoman, Hanmo Zhang, Alan Cheng, Felix Gonzalez Lopez De Turiso, Michael Garrett Johnson
-
Patent number: 11576910Abstract: Provided herein are methods of treating a subject with heart failure, comprising administering to the subject an initial dose of a cardiac sarcomere activator (CSA) for an initial time period, and subsequently administering to the subject a dose of the CSA based on the subject's plasma concentration of the CSA at the end of the initial time period.Type: GrantFiled: June 29, 2018Date of Patent: February 14, 2023Assignees: AMGEN INC., CYTOKINETICS, INC.Inventors: Narimon Honarpour, Fady Malik
-
Patent number: 11479561Abstract: Novel tetrahydroisoquinoline derivative compounds are disclosed herein that may be used as an active ingredient for a pharmaceutical composition, and in particular, for a pharmaceutical composition useful for preventing or treating a disease or condition responsive to modulation of the contractility of the skeletal sarcomere. This may be accomplished, for example, by modulation of the troponin complex of the fast skeletal muscle sarcomere through one or more of fast skeletal myosin, actin, tropomyosin, troponin C, troponin I, and troponin T, and fragments and isoforms thereof. The tetrahydroisoquinoline derivative compounds can thus be used as an agent for preventing or treating 1) neuromuscular disorders, 2) disorders of voluntary muscle, 3) CNS disorders in which muscle weakness, atrophy, and fatigue are prominent symptoms, 4) muscle symptoms stemming from systemic disorders, and 5) dysfunctions of pelvic floor and urethral/anal sphincter muscle.Type: GrantFiled: May 11, 2020Date of Patent: October 25, 2022Assignee: Cytokinetics, IncorporatedInventors: Ippei Sato, Takashi Kamikubo, Masanori Miura, Yuji Matsushima, Hiroaki Tanaka, Yasuhiro Shiina, Susumu Yamaki, Tomoyuki Saito, Hiroshi Kiyohara, Munemichi Ohe, Kayoko Mihara, Bradley Paul Morgan, Fady Malik, Scott Emile Collibee, Luke Ashcraft, Pu-Ping Lu, Jeffrey Michael Warrington, Marc Garard
-
Patent number: 11472773Abstract: Provided are omecamtiv mecarbil dihydrochloride salt forms, compositions and pharmaceutical formulations thereof, and methods for their preparation and use.Type: GrantFiled: July 2, 2020Date of Patent: October 18, 2022Assignee: CYTOKINETICS, INC.Inventors: Sheng Cui, Henry Morrison, Karthik Nagapudi, Shawn D. Walker, Charles Bernard, Karl Bennett Hansen, Neil Fred Langille, Alan Martin Allgeier, Steven Mennen, Jacqueline C. S. Woo, Bradley Paul Morgan, Alex Muci
-
Patent number: 11472796Abstract: Provided are compounds of Formula (I): or a pharmaceutically acceptable salt thereof, wherein A, Z, B, R1, R2, R3, G1, G2, and G3 are as defined herein. Also provided is a pharmaceutically acceptable composition comprising a compound of Formula (I), or a pharmaceutically acceptable salt thereof. Also provided are methods of using a compound of Formula (I), or a pharmaceutically acceptable salt thereof.Type: GrantFiled: September 4, 2020Date of Patent: October 18, 2022Assignee: CYTOKINETICS, INC.Inventors: Chihyuan Chuang, Bradley P. Morgan, Mark Vanderwal, Wenyue Wang, Luke W. Ashcraft
-
Patent number: 11465969Abstract: Provided herein are free base crystalline forms, crystalline salts, and an amorphous salts of omecamtiv mecarbil.Type: GrantFiled: August 16, 2019Date of Patent: October 11, 2022Assignees: CYTOKINETICS, INC., AMGEN INC.Inventors: Henry Morrison, Sheng Cui, Kyle Quasdorf, Evelyn Yanez, Bin Peter Quan, Ron C. Kelly, Sebastien Caille, Lingyun Xiao, David Pearson, Jaclyn Raeburn, Ailsa Golightly, Bradley Morgan, Matthew Peterson, Alex Eberlin, Alexander Oblezov
-
Patent number: 11414424Abstract: Provided are compounds of Formula (I): or a pharmaceutically acceptable salt thereof, wherein R1, R2A, R2B, R3, R4, and R5 are as defined herein. Also provided is a pharmaceutically acceptable composition comprising a compound of Formula (I), or a pharmaceutically acceptable salt thereof. Also provided are methods of using a compound of Formula (I), or a pharmaceutically acceptable salt thereof.Type: GrantFiled: August 30, 2019Date of Patent: August 16, 2022Assignee: CYTOKINETICS, INC.Inventors: Chihyuan Chuang, Bradley P. Morgan, Mark Vanderwal, Luke W. Ashcraft, Kevin Lau
-
Patent number: 11384053Abstract: Provided are certain pharmaceutical formulations of omecamtiv mecarbil and methods for their preparation and use.Type: GrantFiled: September 23, 2019Date of Patent: July 12, 2022Assignee: CYTOKINETICS, INC.Inventors: Mingda Bi, Robert Kuehl
-
Patent number: 11369565Abstract: Provided are compounds of Formula I: or a pharmaceutically acceptable salt thereof, wherein R1, R2, R3, R4, R5, R6, R7, R8, R9, X and mare as defined herein. Also provided is a pharmaceutically acceptable composition comprising a compound of Formula I, or a pharmaceutically acceptable salt thereof. Also provided are methods of using a compound of Formula I, or a pharmaceutically acceptable salt thereof.Type: GrantFiled: July 28, 2020Date of Patent: June 28, 2022Assignee: CYTOKINETICS, INC.Inventors: Zhe Yang, Alex R. Muci, Jeffrey Warrington, Gustave Bergnes, Bradley P. Morgan, Chihyuan Chuang, Antonio Romero, Scott Collibee, Xiangping Qian, Pu-Ping Lu
-
Patent number: 11299479Abstract: The present invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof, pharmaceutical compositions comprising a compound of the invention, a method for manufacturing compounds of the invention and therapeutic uses thereof.Type: GrantFiled: October 12, 2020Date of Patent: April 12, 2022Assignees: CYTOKINETICS, INC., AMGEN INC.Inventors: Luke Ashcraft, Alessandro Boezio, John Butler, Aroop Chandra, Chihyuan Chuang, Scott E. Collibee, Mikkel V. Debenedetto, Vincent DiMassa, Russell Graceffa, Justin Malinowski, David Moebius, Bradley Paul Morgan, Joshua Payette, Antonio Romero, David St. Jean, Jr., Richard Vargas, John Yeoman, Hanmo Zhang, Alan Cheng, Felix Gonzalez Lopez De Turiso, Michael Garrett Johnson
-
Patent number: 11254658Abstract: The present invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof, pharmaceutical compositions comprising a compound of the invention, a method for manufacturing compounds of the invention and therapeutic uses thereof.Type: GrantFiled: March 27, 2020Date of Patent: February 22, 2022Assignees: Amgen Inc., Cytokinetics, Inc.Inventors: Mikkel V. Debenedetto, Justin Malinowski, Joshua Payette, Antonio Romero, David St. Jean, Jr.
-
Patent number: 11142516Abstract: Provided herein is a novel process for the preparation of an amino-pyrimidine and salts thereof. Also provided herein are novel intermediates used in this process and their preparation.Type: GrantFiled: December 26, 2018Date of Patent: October 12, 2021Assignee: Cytokinetics, Inc.Inventors: Matthew Peterson, Kevin Lu, Bradley Morgan, David Morgans, Tohru Fukuyama
-
Patent number: 10975034Abstract: Certain substituted urea derivatives selectively modulate the cardiac sarcomere, for example by potentiating cardiac myosin, and are useful in the treatment of systolic heart failure including congestive heart failure.Type: GrantFiled: July 2, 2019Date of Patent: April 13, 2021Assignee: CYTOKINETICS, INC.Inventors: Bradley Paul Morgan, Alex Muci, Pu-Ping Lu, Erica Anne Kraynack, Todd Tochimoto, David J. Morgans, Jr.